Allelic imbalance in patients with non-small cell lung cancer

Shikeeva A.A.; Kekeeva T.V.; Zavalishina L.É.; Andreeva Yu.Yu.; Frank G.A.

doi:https://doi.org/

Shikeeva A.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Kekeeva T.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Zavalishina L.É.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Andreeva Yu.Yu.

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

SPIN RSCI: 6504-2551
Scopus AuthorID: 8656328100
ORCID: 0000-0003-4749-6608

Frank G.A.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Rosmedtekhnologiĭ, Moskva

ORCID: 0000-0002-3719-5388

Allelic imbalance in patients with non-small cell lung cancer

Authors:

Shikeeva A.A., Kekeeva T.V., Zavalishina L.É., Andreeva Yu.Yu., Frank G.A.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2013;75(2): 3‑8

Read: 878 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Shikeeva AA, Kekeeva TV, Zavalishina LÉ, Andreeva YuYu, Frank GA. Allelic imbalance in patients with non-small cell lung cancer. Russian Journal of Archive of Pathology. 2013;75(2):3‑8. (In Russ.)

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Morphological examination of surgical material of primary lung cancer after neoadjuvant therapy: recommendations and literature review. Russian Journal of Archive of Pathology. 2025;(4):40-46

Classification of non-small cell lung cancer according to the WHO 2021: from morphology to personalized therapy. Russian Journal of Archive of Pathology. 2026;(1):60-67

Mediastinal staging in planning the management of patients with non-small cell lung cancer. P.A. Herzen Journal of Oncology. 2025;(2):57-63

Efficacy of chemoimmunotargeted therapy in patients with advanced non-small cell lung cancer in real clinical practice. P.A. Herzen Journal of Oncology. 2025;(3):63-70

The effectiveness of combined chemotherapy and immunotherapy, and the search for personalized approaches to treating advanced non-small cell lung cancer. P.A. Herzen Journal of Oncology. 2025;(4):37-45

Clinical and economic analysis of nutritional support in the perioperative treatment of lung cancer. P.A. Herzen Journal of Oncology. 2025;(5):54-58

Necessary and sufficient dose at stereotactic radiotherapy in functionally inoperable patients with non-small cell lung cancer. P.A. Herzen Journal of Oncology. 2025;(6):7-12

Abstract:

Non-small cell lung cancer (NSCLC) comprises 80% of all lung cancers and is characterized by multiple genetic alterations such as loss of heterozygosity (LOH) and microsatellite instability (MSI). The aim of the study was to analyze of molecular-genetic alterations in tumor and tissue surrounding the tumor to determine genetic features of different histological types of NSCLC and its possible associations with clinicopathological parameters of patients. A microsatellite analysis of chromosomal regions 12p23.3, 2q35, 3p14.2, 3p22.2, 3p26.3, 9p22.1, 17p13.3 was performed. The frequency of genetic alterations in NSCLC was 50% in average. LOH/MSI in the tumor surrounding tissue at 2 and 5 cm. from tumor was not detected. There were statistically significant associations between LOH and/or MSI and the tumor stage, its histological type and smoking status. The found genetic alterations can be used as molecular markers of squamous cell lung cancer in difficult diagnostic cases and appraised as prognostic markers.

Keywords:

non-small cell lung cancer

allelic imbalance

microsatellite analysis

Authors:

Shikeeva A.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Kekeeva T.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Zavalishina L.É.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Andreeva Yu.Yu.

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

SPIN RSCI: 6504-2551
Scopus AuthorID: 8656328100
ORCID: 0000-0003-4749-6608

Frank G.A.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Rosmedtekhnologiĭ, Moskva

ORCID: 0000-0002-3719-5388

Close metadata

References:

Zochbauer-Muller S., Gazdar A.F., Minna J.D. Molecular pathogenesis of lung cancer. Ann. Rev. Physiol. 2002; 64: 681-708.
Sekido Y., Fong K.M., Minna J.D. Molecular genetics of lung cancer. Ann. Rev. Med. 2003; 54: 73-87.
Mitsuuchi Y., Testa J.R. Cytogenetics and molecular genetics of lung cancer. Am. J. Med. Genet. 2002; 115: 183-8.
Chmara M., Wozniak A., Ochman K., Kobierska G., Dziadziuszko R., Sosinska-Mielcarek K. et al. Loss of heterozygosity at chromosomes 3p and 17p in primary non-small cell lung cancer. Anticancer Res. 2004; 24 (6): 4259-63.
Zienolddiny S., Ryberg D., Arab M.O., Skaug V., Haugen A. Loss of heterozygosity is related to p53 mutations and smoking in lung cancer. Br. J. Cancer. 2001; 84 (2): 226-31.
Woenckhaus M., Grepmeier U., Wild P.J., Merk J., Pfeifer M., Woenckhaus U. et al. Multitarget FISH and LOH analyses at chromosome 3p in non-small cell lung cancer and adjacent bronchial epithelium. Am. J. Clin. Pathol. 2005; 123 (5): 752-61.
Tseng R.C., Chang J.W., Hsien F.J., Chang Y.H., Hsiao C.F., Chen J.T. et al. Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer. Int. J. Cancer 2005; 117 (2): 241-7.
Ahrendt S.A., Decker P.A., Doffek K., Wang B., Xu L., Demeure M.J. et al. Microsatellite instability at selected tetranucleotide repeats is associated with p53 mutations in non-small cell lung cancer. Cancer Res. 2000; 60 (9): 2488-91.
Girard L., Zöchbauer-Müller S., Virmani A.K., Gazdar A.F., Minna J.D. Genomewide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res. 2000; 60 (17): 4894-906.
Mitsudomi T., Oyama T., Nishida K., Ogami A., Osaki T., Sugio K. et al. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin. Cancer Res. 1996; 2 (7): 1185-9.
Zhou X., Kemp B.L., Khuri F.R., Liu D., Lee J.J., Wu W. et al. Prognostic implication of microsatellite profiles in early-stage non-small cell lung cancer. Clin. Cancer Res. 2000; 6 (2): 559-65.
Sanchez-Cespedes M., Ahrendt S.A., Piantadosi S., Rosell R., Monzo M., Wu L. et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res. 2001; 61 (4): 1309-13.
Sanchez-Cespedes M., Decker P.A., Doffek K.M., Esteller M., Westra W.H., Alawi E.A. et al. Increased loss of chromosome 9p21 but not P16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res. 2001; 61 (5): 2092-6.
Marsit C.J., Wiencke J.K., Nelson H.H., Kim D.H., Hinds P.W., Aldape K. et al. Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: association with smoking, TP53, and survival. Cancer Genet. Cytogenet. 2005; 162 (2): 115-21.
Pan H., Califano J., Ponte J.F., Russo A.L., Cheng K.H., Thiagalingam A. et al. Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. Cancer Res. 2005; 65 (5): 1664-9.
Hirao T., Nelson H.H., Ashok T.D., Wain J.C., Mark E.J., Christiani D.C. et al. Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer. Cancer Res. 2001; 61 (2): 612-5.
Grepmeier U., Dietmaier W., Merk J., Wild P.J., Obermann E.C., Pfeifer M. et al. Deletions at chromosome 2q and 12p are early and frequent molecular alterations in bronchial epithelium and NSCLC of long-term smokers. Int. J. Oncol. 2005; 27 (2): 481-8.
Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R. et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450 (7171): 893-8.
Sos M.L., Thomas R.K. Genetic insight and therapeutic targets in squamous-cell lung cancer. Oncogene. 2012; 31 (46): 4811-4. doi: 10.1038/onc.2011.640.
Wen J., Fu J., Zhang W., Guo M. Genetic and epigenetic changes in lung carcinoma and their clinical implications. Mod. Pathol. 2011; 24 (7): 932-43.
Wrage M., Ruosaari S., Eijk P.P., Kaifi J.T., Hollmén J., Yekebas E.F. et al. Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin. Cancer Res. 2009; 15 (5): 1566-74.
Nakayama M., Bennett C.J., Hicks J.L., Epstein J.I., Platz E.A., Nelson W.G. et al. Hypermethylation of the human glutatione S-transferase-π gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epitelium of the prostate. Am. J. Pathol. 2003; 163 (3): 923-33.
Sozzi G., Pastorino U., Moiraghi L., Tagliabue E., Pezzella F., Ghirelli C. et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 1998; 58 (22): 5032-7.
Verri C., Roz L., Conte D., Liloglou T., Livio A., Vesin A. et al. Fragile histidine triad gene inactivation in lung cancer. The European early lung cancer project. Am. J. Respir. Crit. Care Med. 2009; 179 (5): 396-401.
Subramanian J., Govindan R. Lung cancer in never smokers: a review. J. Clin. Oncol. 2007; 25 (5): 561-70.
Tang X., Varella-Garcia M., Xavier A.C., Massarelli E., Ozburn N., Moran C. et al. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev. Res. 2008; 1 (3): 192-200.
Yendamuri S., Vaporciyan A.A., Zaidi T., Feng L., Fernandez R., Bekele N.B. et al. 3p22.1 and 10q22.3 deletions detected by fluorescence in situ hybridization (FISH): a potential new tool for early detection of non-small cell lung cancer (NSCLC). J. Thorac. Oncol. 2008; 3 (9): 979-84.